Abstract
Aims:
To compare the effectiveness of the long-acting anticholinergic, tiotropium with ipratropium/salbutamol in reducing the risk of exacerbations and COPD-related referrals in patients with COPD.
Methods:
Data were obtained from the General Practice Research Database (GPRD). Propensity score matching was used to balance prognostic covariates between treatment groups. Incidence rate ratios and 95% confidence intervals during a 12-month follow-up period were estimated.
Results:
4193 patients (3385, tiotropium; 808, ipratropium/salbutamol) in the GPRD met the inclusion/exclusion criteria. Patients treated with tiotropium had more severe COPD than patients treated with ipratropium/salbutamol. Following propensity score matching, 1222 tiotropium-treated patients and 633 ipratropium/salbutamol-treated patients were included in the final analysis. Incidence rate ratios (95% confidence intervals) were 0.74 (0.64–0.85; p=0.0086) for exacerbations and 0.57 (0.46–0.70; p=0.004) for COPD-related referrals/hospitalisations.
Conclusions:
Tiotropium is associated with a reduced risk of exacerbations and COPD-related referrals and hospitalisation compared to combined ipratropium/salbutamol in patients with COPD.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JG, SL and MC are employees of Boehringer Ingelheim Ltd UK. SK is an employee of Boehringer Ingelheim Corporate. DP has no shares in pharmaceutical companies. He has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory products: 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough. He has received honoraria for advisory panels with; 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough. He or his research team have received funding for research projects from: 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough, Viatris.
Rights and permissions
About this article
Cite this article
Griffin, J., Lee, S., Caiado, M. et al. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim Care Respir J 17, 104–110 (2008). https://doi.org/10.3132/pcrj.2008.00024
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3132/pcrj.2008.00024
This article is cited by
-
Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
Respiratory Research (2020)
-
Indacaterol/Glycopyrronium Combination for COPD
Pulmonary Therapy (2017)